Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 HCV-infected patients with severe renal impairment

Authors
Category Primary study
JournalGut
Year 2018
This article has no abstract
Epistemonikos ID: 25b22b694acd29de20b23d53151e48f840421f36
First added on: Feb 09, 2025